

Inhaled therapy

Breathlessness and/or exercise limitation

SABA or SAMA as required*

Exacerbations or persistent breathlessness

FEV₁ ≥ 50%

FEV₁ < 50%

LABA

LAMA**
Offer LAMA in preference to regular SAMA four times a day

LABA + ICS in a combination inhaler
Consider LABA + LAMA if ICS declined or not tolerated

LAMA**
Offer LAMA in preference to regular SAMA four times a day

LABA + ICS in a combination inhaler
Consider LABA + LAMA if ICS declined or not tolerated

LAMA + LABA + ICS

Persistent exacerbations or breathlessness

— Offer therapy
- - - - - Consider therapy

- Choose a drug based on the person's symptomatic response and preference, the drug's side effects, potential to reduce exacerbations and cost.
- Do not use oral corticosteroid reversibility tests to identify patients who will benefit from inhaled corticosteroids.
- Be aware of the potential risk of developing side effects (including non-fatal pneumonia) in people with COPD treated with inhaled corticosteroids and be prepared to discuss this with patients.

* SABA as required may continue at all stages; ** Discontinue SAMA.
SABA, short-acting beta₂ agonist; SAMA, short-acting muscarinic antagonist.